BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11056320)

  • 1. Update on raloxifene to prevent endometrial-breast cancer.
    Goldstein SR
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene: risks and benefits.
    Barrett-Connor E
    Ann N Y Acad Sci; 2001 Dec; 949():295-303. PubMed ID: 11795366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.
    DeMichele A; Troxel AB; Berlin JA; Weber AL; Bunin GR; Turzo E; Schinnar R; Burgh D; Berlin M; Rubin SC; Rebbeck TR; Strom BL
    J Clin Oncol; 2008 Sep; 26(25):4151-9. PubMed ID: 18757329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials.
    Smith RE
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):4-13. PubMed ID: 14613021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?
    Sismondi P; Biglia N; Roagna R; Ponzone R; Ambroggio S; Sgro L; Cozzarella M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S74-6. PubMed ID: 11056328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of SERMs on the endometrium.
    Goldstein SR
    Ann N Y Acad Sci; 2001 Dec; 949():237-42. PubMed ID: 11795358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
    O'Regan RM; Gajdos C; Dardes RC; De Los Reyes A; Park W; Rademaker AW; Jordan VC
    J Natl Cancer Inst; 2002 Feb; 94(4):274-83. PubMed ID: 11854389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.